Biology subjects

Annala, M.

Publications and source records attributed to Annala, M..

4 recordsLinked to original sources

bioRxiv2026

Celiac disease patient derived iPSC small intestinal epithelial cells are more persistent under cytokine stimuli than healthy control cells

Background & AimsCeliac disease is a wheat-induced immune-mediated enteropathy. Intestinal organoid models for adult stem cell-based celiac disease exist, but planar intestinal models derived from celiac disease patients that would allow direct assessment from both sides of the epithelium have been lacking. We aimed to bridge this gap by setting up a two-dimensional in vitro model based on small intestinal epithelial cells (SIECs) derived from induced pluripotent stem cells (iPSC) from celiac disease patients. MethodsIPSCs from celiac disease and control patients were sequentially differentiated towards SIECs. The models applicability was tested under cytokine stimuli. ResultsCeliac disease and control patient iPSCs matured similarly towards SIECs. However, they had inherent gene expression differences in inflammation- and immune-related genes, such as IRF1 and HLA-DRB1. Both iPSC-SIECs responded in a SIEC-specific manner to the cytokine stimulation. The response in celiac disease iPSC-SIECs was attenuated compared with that of control iPSC-SIECs. ConclusionsThe data confirm that iPSC-derived SIECs represent an appropriate platform for studying inflammation-associated enteropathies, such as celiac disease, but also suggest that there might be inherent patient-specific or cell type-specific differences in the responses.

cell biology↗

bioRxiv2025

Integrative multi-modal analysis reveals the contribution of noncoding RNAs to post-treatment progression of IDH-mutant astrocytomas

IDH-mutant (IDHmut) astrocytomas typically arise as grade 2-3 tumors, but a subset of them progress to grade 4 after treatment, significantly worsening the prognosis. It is unresolved how noncoding RNAs (ncRNAs) contribute to this tumor progression. To characterize ncRNAs regulatory roles, we profiled and analyzed the coding and noncoding transcriptomes of matched tumor samples before and after progression to grade 4 in IDHmut astrocytoma patients. By integrating our data with public primary and matched tumor cohorts, we found that upregulated protein-coding genes in progressed tumors overlapped with those in primary grade 4 tumors and were linked to cell proliferation. In contrast, downregulated genes differed between primary and post-treatment grade 4 tumors. A large fraction of genes that were downregulated only in the post-treatment setting were associated with decreased cell differentiation. We identified 53 progression-related ncRNAs predicted to regulate 125 differentially expressed genes. Gene regulatory network analysis revealed their involvement in cell cycle control, extracellular matrix (ECM) organization, and neural differentiation. Notably, hsa-let-7b-3p, a tumor suppressor microRNA, showed recurrent hemizygous deletions and downregulation after post-therapy progression. The long noncoding RNA (lncRNA) PVT1 was recurrently gained and upregulated in grade 4 tumors. The lncRNA NEAT1, previously linked to treatment resistance, was especially upregulated post-treatment and had the highest number of predicted targets (n=38), many related to ECM organization. Overall, our findings highlight the role of ncRNAs in the post-treatment progression of IDHmut astrocytomas, offering new insights into mechanisms of their malignancy.

cancer biology↗

bioRxiv2024

Constrained hypermutation and absence of TERT promoter mutations in Lynch syndrome-associated urothelial cancer

Lynch syndrome (LS) is a hereditary condition characterized by defective DNA mismatch repair (MMR) and high incidence of several cancers, including urothelial cancers (UC) of the upper urinary tract and bladder. We set out to study the somatic landscape of LS-associated urothelial cancer (LS-UC) by analyzing 41 surgical tumor samples and 3 urine DNA samples from 34 LS-UC patients. We show that telomerase reverse transcriptase (TERT) promoter mutations found in 83% of sporadic UC are almost completely absent (5%) in LS-UC (p < 0.00001). Instead, all LS-UC carried a 5-methylcytosine deamination (CG>TG) and microsatellite instability driven mutation landscape characterized by highly frequent ARID1A (82%), FGFR3 (80%), and KMT2D (78%) mutations, as well as preferential usage of CG>TG mutation hotspots. We propose that the scarcity of TERT promoter mutations in LS-UC is due to inability to create the necessary GABP binding motif (5-GGAA) through CG>TG mutation or microsatellite instability. Our data shows that LS-UC represents a disease entity with unique genomic characteristics.

cancer biology↗

bioRxiv2020

Chromatin accessibility analysis uncovers regulatory element landscape in prostate cancer progression

Aberrant oncogene functions and structural variation alter the chromatin structure in cancer cells. While gene regulation by chromatin states has been studied extensively, chromatin accessibility and its relevance in aberrant gene expression during prostate cancer progression is not well understood. Here, we report a genome-wide chromatin accessibility analysis of clinical tissue samples of benign prostatic hyperplasia (BPH), untreated primary prostate cancer (PC) and castration-resistant prostate cancer (CRPC) and integrative analysis with transcriptome, methylome, and proteome profiles of the same samples to uncover disease-relevant regulatory elements and their association to altered gene expression during prostate cancer progression. While promoter accessibility is consistent during disease initiation and progression, at distal sites chromatin accessibility is variable enabling transcription factors (TFs) binding patterns that are differently activated in different patients and disease stages. We identify consistent progression-related chromatin alterations during the progression to CRPC. By studying the TF binding patterns, we demonstrate the activation and suppression of androgen receptor-driven regulatory programs during PC progression and identify complementary TF regulatory modules characterized by e.g. MYC and glucocorticoid receptor. By correlation analysis we assign at least one putative regulatory region for 62% of genes and 85% of proteins differentially expressed during prostate cancer progression. Taken together, our analysis of the chromatin landscape in PC identifies putative regulatory elements for the majority of cancer-associated genes and characterizes their impact on the cancer phenotype.

cancer biology↗